Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 2/3 2Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 16Terminated 8Active not recruiting 8Recruiting 7Not yet recruiting 4Withdrawn 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Multiple Myeloma 3Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 13Nivolumab 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Radiotherapy 6Cisplatin 6fludarabine phosphate 5Interleukin-2 5Injections 5Doxorubicin 5tislelizumab 4daratumumab 4Paclitaxel 4Ipilimumab 4Immune Checkpoint Inhibitors 4Drug Therapy 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3trastuzumab deruxtecan 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Rituximab 3Radiosurgery 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × daratumumab × Clear all
NCT07513129 2026-04-21

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07221032 2026-04-14

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

Medical College of Wisconsin

Phase 1 Not yet recruiting
12 enrolled
Plasma cell

Multiple Myeloma

NCT07400744 2026-02-10

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
102 enrolled
Plasma cell

Multiple Myeloma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
90 enrolled
BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡